Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.
Identifieur interne : 000611 ( PubMed/Checkpoint ); précédent : 000610; suivant : 000612Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.
Auteurs : Barbara C. Tilley [États-Unis] ; Nancy R. Lapelle [États-Unis] ; Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis]Source :
- Journal of Parkinson's disease [ 1877-718X ] ; 2014.
English descriptors
- KwdEn :
- MESH :
- diagnosis : Parkinson Disease.
- standards : Societies, Medical, Surveys and Questionnaires.
- Humans, Severity of Illness Index.
Abstract
Cognitive pretesting, a qualitative step in scale development, precedes field testing and assesses the difficulty of instrument completion for examiners and respondents. Cognitive pretesting assesses respondent interest, attention span, discomfort, and comprehension, and highlights problems with the logical structure of questions/response options that can affect understanding. In the past this approach was not consistently used in the development or revision of movement disorders scales.
DOI: 10.3233/JPD-130310
PubMed: 24613868
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24613868Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.</title><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C" last="Tilley">Barbara C. Tilley</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, University of Texas School of Public Health at Houston, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, University of Texas School of Public Health at Houston, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Lapelle, Nancy R" sort="Lapelle, Nancy R" uniqKey="Lapelle N" first="Nancy R" last="Lapelle">Nancy R. Lapelle</name><affiliation wicri:level="4"><nlm:affiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region><settlement type="city">Amherst (Massachusetts)</settlement></placeName><orgName type="university">Université du Massachusetts</orgName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24613868</idno><idno type="pmid">24613868</idno><idno type="doi">10.3233/JPD-130310</idno><idno type="wicri:Area/PubMed/Corpus">000814</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000814</idno><idno type="wicri:Area/PubMed/Curation">000814</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000814</idno><idno type="wicri:Area/PubMed/Checkpoint">000814</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000814</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.</title><author><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C" last="Tilley">Barbara C. Tilley</name><affiliation wicri:level="2"><nlm:affiliation>Division of Biostatistics, University of Texas School of Public Health at Houston, Houston, TX, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, University of Texas School of Public Health at Houston, Houston, TX</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Lapelle, Nancy R" sort="Lapelle, Nancy R" uniqKey="Lapelle N" first="Nancy R" last="Lapelle">Nancy R. Lapelle</name><affiliation wicri:level="4"><nlm:affiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region><settlement type="city">Amherst (Massachusetts)</settlement></placeName><orgName type="university">Université du Massachusetts</orgName></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><series><title level="j">Journal of Parkinson's disease</title><idno type="eISSN">1877-718X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term><term>Parkinson Disease (diagnosis)</term><term>Severity of Illness Index</term><term>Societies, Medical (standards)</term><term>Surveys and Questionnaires (standards)</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Societies, Medical</term><term>Surveys and Questionnaires</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cognitive pretesting, a qualitative step in scale development, precedes field testing and assesses the difficulty of instrument completion for examiners and respondents. Cognitive pretesting assesses respondent interest, attention span, discomfort, and comprehension, and highlights problems with the logical structure of questions/response options that can affect understanding. In the past this approach was not consistently used in the development or revision of movement disorders scales.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24613868</PMID><DateCreated><Year>2014</Year><Month>09</Month><Day>03</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1877-718X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Journal of Parkinson's disease</Title><ISOAbbreviation>J Parkinsons Dis</ISOAbbreviation></Journal><ArticleTitle>Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.</ArticleTitle><Pagination><MedlinePgn>395-404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JPD-130310</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive pretesting, a qualitative step in scale development, precedes field testing and assesses the difficulty of instrument completion for examiners and respondents. Cognitive pretesting assesses respondent interest, attention span, discomfort, and comprehension, and highlights problems with the logical structure of questions/response options that can affect understanding. In the past this approach was not consistently used in the development or revision of movement disorders scales.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We applied qualitative cognitive pretesting using testing guides in development of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The guides were based on qualitative techniques, verbal probing and "think-aloud" interviewing, to identify problems with the scale from the patient and rater perspectives. English-speaking Parkinson's disease patients and movement disorders specialists (raters) from multiple specialty clinics in the United States, Western Europe and Canada used the MDS-UPDRS and completed the testing guides.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two rounds of cognitive pretesting were necessary before proceeding to field testing of the revised scale to assess clinimetric properties. Scale revisions based on cognitive pretesting included changes in phrasing, simplification of some questions, and addition of a reassuring statement explaining that not all PD patients experience the symptoms described in the questions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The strategy of incorporating cognitive pretesting into scale development and revision provides a model for other movement disorders scales. Cognitive pretesting is being used in translating the MDS-UPDRS into multiple languages to improve comprehension and acceptance and in the development of a new Unified Dyskinesia Rating Scale for Parkinson's disease patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tilley</LastName><ForeName>Barbara C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, University of Texas School of Public Health at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>LaPelle</LastName><ForeName>Nancy R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Division of Preventive and Behavioral Medicine, University of Massachusetts, Worcester, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stebbins</LastName><ForeName>Glenn T</ForeName><Initials>GT</Initials><AffiliationInfo><Affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>MDS-UPDRS Task Force</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 NS043127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Parkinsons Dis</MedlineTA><NlmUniqueID>101567362</NlmUniqueID><ISSNLinking>1877-7171</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2002 Sep;17(5):867-76</RefSource><PMID Version="1">12360535</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008 Nov 15;23(15):2129-70</RefSource><PMID Version="1">19025984</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pain Symptom Manage. 2009 Feb;37(2):233-45</RefSource><PMID Version="1">18676118</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 2008 Dec;17(10):1239-46</RefSource><PMID Version="1">18850327</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Patient Educ Couns. 2009 Oct;77(1):136-43</RefSource><PMID Version="1">19395226</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2007 Jan;22(1):41-7</RefSource><PMID Version="1">17115387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Health Serv Res. 2005 Dec;40(6 Pt 2):2037-56</RefSource><PMID Version="1">16316437</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cognitive pretesting</Keyword><Keyword MajorTopicYN="N">Modified Unified Parkinson's Disease Rating Scale</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">scale development</Keyword></KeywordList><CoiStatement>The authors have no conflict of interest to report.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Goetz</LastName><ForeName>Christopher G</ForeName><Initials>CG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tilley</LastName><ForeName>Barbara C</ForeName><Initials>BC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stebbins</LastName><ForeName>Glenn T</ForeName><Initials>GT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fahn</LastName><ForeName>Stanley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez-Martin</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sampaio</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dodel</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holloway</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulisevsky</LastName><ForeName>Jaime</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lang</LastName><ForeName>Anthony E</ForeName><Initials>AE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leurgans</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeWitt</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nyenhuis</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olanow</LastName><ForeName>C Warren</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schrag</LastName><ForeName>Anette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teresi</LastName><ForeName>Jeanne A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Jacobus J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaPelle</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24613868</ArticleId><ArticleId IdType="pmc">PMC5086096</ArticleId><ArticleId IdType="pii">5T621814783126P6</ArticleId><ArticleId IdType="doi">10.3233/JPD-130310</ArticleId><ArticleId IdType="mid">NIHMS735119</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li><li>Massachusetts</li><li>Texas</li></region><settlement><li>Amherst (Massachusetts)</li></settlement><orgName><li>Université du Massachusetts</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Tilley, Barbara C" sort="Tilley, Barbara C" uniqKey="Tilley B" first="Barbara C" last="Tilley">Barbara C. Tilley</name></region><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name><name sortKey="Lapelle, Nancy R" sort="Lapelle, Nancy R" uniqKey="Lapelle N" first="Nancy R" last="Lapelle">Nancy R. Lapelle</name><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T" last="Stebbins">Glenn T. Stebbins</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000611 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000611 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24613868
|texte= Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24613868" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |